|
Hematology/Oncology Research Studies: Open for Enrollment | Date: 01/26/21 |
|---|
| NCT#/Phase: | NCT03067181 Phase 3 |
|---|---|
| IRB#: | 2017-110 |
| Description: | The aim of this study for low and standard risk germ cell tumor (GCT) patients is to minimize toxicity by reducing therapy while maintaining current survival rates. The trial will eliminate chemotherapy for low risk patients who are likely cured with surgery and will observe the salvage rates among those who recur. Among standard risk patients the trial will evaluate whether cisplatin, which is the standard-of-care in COG, can be replaced with a less toxic alternative platin analogue, carboplatin. |
| Inclusion: | All newly diagnosed patients with histologic verification of a primary extracranial germ cell tumor are potentially eligible for this trial. |
| Enrollment Status: | Open for enrollment |
| Sponsor: | COG |
| Principal Investigator(s): | Carla Golden, MD |
| Contact(s): | Sheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611) COG CRA Office (510-428-3885 x8334) |
| Study Link: | https://clinicaltrials.gov/ct2/show/NCT03067181 |